We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01048255
Recruitment Status : Completed
First Posted : January 13, 2010
Last Update Posted : January 27, 2014
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
The purpose of this study is to determine the safety, tolerability, and efficacy of VX-765 in subjects with Treatment-resistant Partial Epilepsy

Condition or disease Intervention/treatment Phase
Partial Epilepsy Drug: VX-765 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
Study Start Date : January 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Arm Intervention/treatment
Experimental: VX-765 Drug: VX-765
300mg Oral Tablet, 900mg TID

Primary Outcome Measures :
  1. Safety and tolerability (vital sign assessments, physical and neurological examinations, laboratory assessments, and adverse events) [ Time Frame: 18 weeks ]

Secondary Outcome Measures :
  1. Percent reduction in seizure frequency [ Time Frame: 6 weeks ]
  2. Percent of subjects with 50% or greater reduction in seizure frequency [ Time Frame: 6 weeks ]
  3. Percent of subjects that become seizure free [ Time Frame: 2 weeks ]
  4. Percent of subjects who discontinue study drug treatment [ Time Frame: 6 weeks ]
  5. Plasma levels of study drug and other concomitant antiepileptic drugs [ Time Frame: 13 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects that are male or female aged 18 to 64 years (inclusive) with a body mass index between 18 and 35 (kg/m2)
  • Subjects must have a diagnosis and history of treatment resistant partial onset seizures for which they are taking 1 to 4 concomitant antiepileptic drugs (AED). Treatment resistance is defined as failure to achieve seizure freedom despite adequate use of 2 different AEDs. All AED doses must remain stable for 4 weeks prior to the Screening Visit and throughout the entire study
  • Subjects must have had at least 1 electroencephalogram (EEG) consistent with partial epilepsy and a brain magnetic resource imaging (MRI) or computed tomography (CT) scan within 5 years of Screening Visit negative for other confounding conditions
  • Subjects must have had at least 6 observable partial seizures in 6 weeks prior to randomization, with at least 1 seizure per week during 3 of the 6 weeks within the Baseline Period
  • Subjects who are male or female must agree to use acceptable contraceptive methods as defined in the protocol
  • Subjects who are in otherwise good health

Exclusion Criteria:

  • Subjects with a history of non-epileptic transient alterations in consciousness
  • Subjects who have a history of status epilepticus in the past 12 months
  • Subjects whose seizure frequency cannot be quantified
  • Subjects who have significant medical illness including kidney, liver, pulmonary or gastrointestinal disease; or unstable or poorly controlled conditions
  • Subjects who have clinically significant psychiatric illness
  • Subjects with a positive drug screen (excluding any allowed prescribed medications) and history of alcoholism or drug addiction within past 2 years
  • Males subjects that have a female partner of childbearing potential who do not agree to use medically approved methods of birth control
  • Male subjects that have a female partner who is pregnant, nursing, or is planning to become pregnant during the study period, or within 90 days of the last dose of study drug
  • Female subjects who are pregnant or lactating, or who are of reproductive potential who do not agree to use medically approved birth-control methods
  • Subjects with a current or prior history of illness precluding them from immunomodulatory therapy (e.g. history of recurrent infections)
  • Subjects with active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
  • Subjects who have participated in any other clinical trials involving an investigational product or device and have received the last dose of study drug within 45 days or 5 half-lives of the Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01048255

Layout table for location information
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Newport Beach, California, United States
United States, Florida
Miami, Florida, United States
Sarasota, Florida, United States
United States, Illinois
Chicago, Illinois, United States
United States, Maryland
Baltimore, Maryland, United States
Bethesda, Maryland, United States
United States, Missouri
Chesterfield, Missouri, United States
United States, New Jersey
New Jersey
Hackensack, New Jersey, United States
United States, New York
New York
New York, New York, United States
United States, Pennsylvania
Philidelphia, Pennsylvania, United States
United States, Virginia
Charlottesville, Virginia, United States
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Layout table for investigator information
Study Director: Chris Wright, MD, PhD Vertex Pharmaceuticals Incorporated
Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT01048255    
Other Study ID Numbers: VX09-765-401
First Posted: January 13, 2010    Key Record Dates
Last Update Posted: January 27, 2014
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases